297 related articles for article (PubMed ID: 14762239)
1. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.
Opolka JL; Rascati KL; Brown CM; Gibson PJ
Psychiatr Serv; 2004 Feb; 55(2):151-6. PubMed ID: 14762239
[TBL] [Abstract][Full Text] [Related]
2. Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.
Opolka JL; Rascati KL; Brown CM; Barner JC; Johnsrud MT; Gibson PJ
J Clin Psychiatry; 2003 Jun; 64(6):635-9. PubMed ID: 12823076
[TBL] [Abstract][Full Text] [Related]
3. Role of ethnicity in predicting antipsychotic medication adherence.
Opolka JL; Rascati KL; Brown CM; Gibson PJ
Ann Pharmacother; 2003 May; 37(5):625-30. PubMed ID: 12708934
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
5. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia.
Kuno E; Rothbard AB
Am J Psychiatry; 2002 Apr; 159(4):567-72. PubMed ID: 11925294
[TBL] [Abstract][Full Text] [Related]
6. New generation antipsychotics for first episode schizophrenia.
Rummel C; Hamann J; Kissling W; Leucht S
Cochrane Database Syst Rev; 2003; (4):CD004410. PubMed ID: 14584012
[TBL] [Abstract][Full Text] [Related]
7. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
8. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
9. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
Ren XS; Kazis LE; Lee AF; Huang YH; Hamed A; Cunningham F; Herz L; Miller DR
Schizophr Res; 2005 Sep; 77(2-3):167-77. PubMed ID: 15894460
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
Gianfrancesco F; Pesa J; Wang RH
J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
[TBL] [Abstract][Full Text] [Related]
11. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.
Yoon HJ; Park KM; Choi WJ; Choi SH; Park JY; Kim JJ; Seok JH
BMC Psychiatry; 2013 Sep; 13():240. PubMed ID: 24074357
[TBL] [Abstract][Full Text] [Related]
13. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
15. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA
Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501
[TBL] [Abstract][Full Text] [Related]
16. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).
García-Cabeza I; Gómez JC; Sacristán JA; Edgell E; González de Chavez M
BMC Psychiatry; 2001; 1():7. PubMed ID: 11835695
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
18. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.
Kreyenbuhl J; Slade EP; Medoff DR; Brown CH; Ehrenreich B; Afful J; Dixon LB
Schizophr Res; 2011 Sep; 131(1-3):127-32. PubMed ID: 21576008
[TBL] [Abstract][Full Text] [Related]
19. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
